Sep 10,2024

Dario Publishes New Research Revealing How Physical Activity Mediates the Impact of Depression on Blood Glucose Levels in Individuals with Diabetes or Prediabetes

DarioHealth published a new study in Frontiers in Endocrinology demonstrating how physical activity, specifically walking, mitigates the impact of depression on blood glucose levels in individuals with type 2 diabetes (T2D) or prediabetes. The study analyzed data from 989 Dario members who tracked their steps and blood glucose (BG) levels over 12 months. Key findings showed that members with depression had higher average BG levels, but walking significantly reduced these levels., and a statistically significant link was found between depression and BG levels, which was mediated by the number of daily steps. The study supports integrating physical activity, such as walking, into treatment protocols for T2D and depression.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 05,2024

New Clinical Study Finds Sword Saves Employers $2,900 per Member in MSK-Related Productivity Loss Annually

The study aimed to evaluate the economic impact of Sword's digital musculoskeletal (MSK) care platform on employee productivity and healthcare savings for employers. The study involved over 5,000 employees from various industries across the United States, all of whom had suffered from chronic MSK pain for at least 12 weeks. Participants were enrolled in a 12-week digital MSK care program called "Thrive," which included several key components: home-based exercises, educational materials, cognitive behavioral therapy (CBT), and ongoing support from a Doctor of Physical Therapy. On average, the program resulted in savings of $243 per participant per month, which could be projected to nearly $2,916 per participant annually. These savings were consistent across different industries, although sectors such as finance and information saw the highest savings at around $300 per participant per month. Participants reported significant enhancements in their non-work-related daily activities, indicating an overall improvement in quality of life.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Sep 09,2024

Sustained 3-Year Improvement of Glucose Control With Hybrid Closed Loop in Children With Type 1 Diabetes While Going Through Puberty

The study aims to evaluate the impact of prolonged hybrid closed loop (HCL) use in children with type 1 diabetes (T1D) on glucose control and BMI throughout pubertal progression. The researchers used a prospective multicenter extension study following the Free-Life Kid AP (FLKAP) HCL trial. The 9-month previously reported FLKAP trial included 119 prepubertal children (aged 6–12 years). During the extension study, participants could continue to use HCL for 30 months (M9 to M39). One hundred seventeen children completed the extension study, with mean age 10.1 years (minimum to maximum, 6.8–14.0) at the beginning. Improvement of HbA1c obtained in the FLKAP trial was significantly sustained during extension and did not differ between children who entered puberty at M24 and patients who remained prepubertal. The results showed that prolonged use of HCL can safely and effectively mitigate impairment of glucose control usually associated with pubertal progression without impact on BMI in children with T1D.

CLINICAL STUDY

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Aug 01,2024

New AI Tool Predicts Risk for Chronic Pain in Cancer Patients

A new study by researchers at the University of Florida and other institutions uses AI to predict which breast cancer patients are most likely to develop chronic pain, a condition that affects about one-third of cancer patients and can significantly impact their quality of life. The AI model, developed using data from over 1,000 patients, correctly predicted chronic pain in more than 80% of cases. Key risk factors include anxiety, depression, prior cancer diagnoses, and certain infections. The findings, published in the Journal of Nursing Scholarship on July 26, highlight the potential of AI to personalize treatments by identifying at-risk patients early on. Integrating this model into healthcare systems would require further research, but it could enhance doctors' ability to tailor treatments to individual needs.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Aug 27,2024

The results of the ELAINE study, published in Epilepsia Open, confirm the positive impact of emyna from GAIA Group

Despite the availability of pharmacological treatment for seizures, people with epilepsy (PwE) commonly experience impairments in quality of life (QoL). The objective of this study was to examine the effectiveness of emyna, a fully automated digital intervention based on cognitive behavioral therapy (CBT) techniques, in improving health-related QoL among PwE who reported impairments in QoL. A pragmatic randomized controlled trial was conducted with N = 438 PwE who were assigned to the intervention group (n = 216), which used emyna alongside treatment as usual (TAU), or the control group (n = 222), which received TAU only. Findings from the intent-to-treat analyses showed that after 3 months, participants in the intervention group experienced significant and clinically relevant improvements in health-related QoL compared to the control group. This study extends previous research by demonstrating that emyna facilitates improvements in QoL in a diverse group of PwE treated in routine care settings. This CBT-based digital intervention therefore presents a convenient and cost-effective addition to healthcare providers' treatment repertoire.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Sep 04,2024

A New AI Tool for Cancer

Scientists at Harvard Medical School have developed an AI model, named CHIEF, capable of performing a wide range of cancer diagnostic tasks, as detailed in Nature on September 4, 2024. Unlike traditional AI systems that focus on specific cancer types or tasks, CHIEF can evaluate 19 types of cancer, predict patient outcomes, and identify treatment responses with greater accuracy. Trained on millions of tumor images, CHIEF outperforms existing AI systems in detecting cancer cells, predicting tumor genetic profiles, and forecasting patient survival. It achieved high accuracy (up to 96%) in tasks such as cancer detection and genomic mutation identification. CHIEF also identifies molecular characteristics of tumors, providing insights into cancer aggressiveness and potential treatment responses.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Sep 04,2024

Click Therapeutics Announces CT-132 Met Primary Endpoint for the Reduction of Monthly Migraine Days in ReMMi-D Pivotal Trial

Click Therapeutics announced meeting the primary endpoint in the pivotal randomized, double-blind, controlled, decentralized, study of CT-132 for the preventive treatment of migraine, ReMMi-D (Reduction in Monthly Migraine Days, NCT05853900). At completion of the study, CT-132 showed a statistically significant reduction in monthly migraine days (MMDs) following 12 weeks of treatment compared to sham, (n=568, ITT population, -0.9 MMDs, p=0.005), with the treatment arm experiencing -3.04 MMDs by end of treatment. Engagement and adherence were high and sustained over the full 12-week duration of the treatment. Both the intervention and sham groups demonstrated nearly 100% median completion of daily tasks.

CLINICAL STUDY

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 18,2024

Comparative Effectiveness of Three Digital Interventions for Adults Seeking Psychiatric Services

There is a substantial gap between demand for and availability of mental health services. Digital mental health interventions (DMHIs) are promising tools for bridging this gap, yet little is known about their comparative effectiveness. In this study, researchers aimed to assess whether patients randomized to a cognitive behavioral therapy (CBT)–based or mindfulness-based DMHI had greater improvements in mental health symptoms than patients randomized to the enhanced personalized feedback (EPF)–only DMHI. Participants were randomized to 1 of 5 intervention arms: (1) EPF only; (2) Silvercloud only; (3) Silvercloud plus EPF; (4) Headspace only; and (5) Headspace plus EPF. The results showed that the magnitude of change was not significantly different across the 5 arms. Additionally, the groups did not differ in decrease in anxiety or substance use symptoms. However, the Headspace arms reported significantly greater improvements on a suicidality measure subscale compared with the Silvercloud arms. The findings suggest that DMHIs may provide support for patients during waiting list–related delays in care. 

CLINICAL STUDY

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 29,2024

Breakthrough study shows AI digital program as effective as human therapy for anxiety

A new study by ieso Digital Health in collaboration with the NHS and NIHR BioResource reveals that its AI-driven digital programme delivered results comparable to traditional human-led therapy for generalized anxiety.  Developed by expert clinicians and using the latest advances in AI, the ieso Digital Programme offers a six-module course facilitated by a conversational agent. It provides real-time, tailored interactions to teach users skills to manage their anxiety based on Cognitive Behavioral Therapy (CBT) principles. In ieso’s landmark study of 300 volunteers with mild to severe anxiety, 82% of participants who used the programme for up to nine weeks showed a clinically meaningful decrease in anxiety symptoms, which can include worry, sleeplessness and fatigue. Even those with severe anxiety benefited from marked improvements, and over half experienced a reduction in symptoms within two weeks, on average. The programme, benchmarked against carefully matched NHS patient data (n=767), proved as effective as human-led therapy. In the US, variants of the ieso digital programme are being piloted with payers and health systems. The program will be rolled out with selected UK partners in late 2024.

CLINICAL STUDY

#cbt

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jul 12,2024

Study of digital self-management service shows 50% reduction in A&E attendances for COPD

The study team evaluating the Lenus Treat: COPD Supported Self-Management Service have released early evaluation data and an economic model which indicated the service is both less costly and  more effective than standard care. The Dynamic Rose study, funded by the Small Business Research Initiative (SBRI), recruited more than 100 patients from Hull University Teaching Hospitals NHS Trust (HUTH) following an admission. Patients were then provided with a digital  service to help them to recognise and self-report their symptoms, access self-management  resources, and to directly communicate with the clinical team if there was cause for concern. In addition to the 50 per cent reduction in A&E attendance, interim results of the Dynamic Rose study also indicated a number of other benefits as a result of the Lenus Treat: COPD Supported Self Management Service. As part of an independent health economic evaluation undertaken by the York Health Economic  Consortium funded through the project, the digital support service was modelled to be more effective and £1,749 less costly than standard care, per patient per annum.

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY